Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Johnson & Johnson’s stock rose 2.4% in premarket trading, enough to pace the Dow Jones Industrial Average’s early gainers.

In the second quarter, J&J’s worldwide oncology sales shot up more than 20 per cent, offsetting declines in sales of its ...

RXRX is scaling its AI-driven drug discovery technology through billion-dollar pharma deals and strategic tech alliances.

Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for our updates on GILD and MRK.

President Donald Trump says that he was likely to impose tariffs on pharmaceuticals as soon as the end of this month.

Shares of Johnson & Johnson climbed 6.8% in morning trading, enough to pace the S&P 500 index's SPX gainers. They were also headed for their biggest one-day gain and best postearnings reaction since ...

Hong Kong-based Sino Biopharm, which took its stake in LaNova when it participated in the company's $42 million financing ...

Trump plans steep tariffs on pharmaceuticals and semiconductors by July-end, eyes India trade deal as part of broader ...

GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity or type 2 diabetes, researchers reported in San Francisco at ENDO 2025, the ...